Sleep and circadian dysregulation in depressive illness. Pharmacological implications.

Autores
Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Brown, Gregory M.. No especifíca;
Materia
DEPRESION
SUEÑO
RITIMOS CIRCADIANOS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/194457

id CONICETDig_8bf6b6d1af338728960bbd111816b253
oai_identifier_str oai:ri.conicet.gov.ar:11336/194457
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Sleep and circadian dysregulation in depressive illness. Pharmacological implications.Cardinali, Daniel PedroPandi Perumal, Seithikurippu R.Brown, Gregory M.DEPRESIONSUEÑORITIMOS CIRCADIANOShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pandi Perumal, Seithikurippu R.. No especifíca;Fil: Brown, Gregory M.. No especifíca;Giovanni Fioriti2011-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194457Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-3381724-4935CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.clinicalneuropsychiatry.org/download/sleep-and-circadian-dysregulation-in-depressive-illness-pharmacological-implications/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:43:41Zoai:ri.conicet.gov.ar:11336/194457instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:43:41.228CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
title Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
spellingShingle Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
Cardinali, Daniel Pedro
DEPRESION
SUEÑO
RITIMOS CIRCADIANOS
title_short Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
title_full Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
title_fullStr Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
title_full_unstemmed Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
title_sort Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
author_role author
author2 Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
author2_role author
author
dc.subject.none.fl_str_mv DEPRESION
SUEÑO
RITIMOS CIRCADIANOS
topic DEPRESION
SUEÑO
RITIMOS CIRCADIANOS
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Brown, Gregory M.. No especifíca;
description Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.
publishDate 2011
dc.date.none.fl_str_mv 2011-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/194457
Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-338
1724-4935
CONICET Digital
CONICET
url http://hdl.handle.net/11336/194457
identifier_str_mv Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-338
1724-4935
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.clinicalneuropsychiatry.org/download/sleep-and-circadian-dysregulation-in-depressive-illness-pharmacological-implications/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Giovanni Fioriti
publisher.none.fl_str_mv Giovanni Fioriti
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614472387264512
score 13.070432